Table 1.
Selected characteristics of the near‐patient assays evaluated in the present study
| Assay | Manufacturer | Influenza type detected | Recommended specimen | Recommended incubation period | Sensitivity for influenza A viruses | Specificity for influenza A viruses | ||
|---|---|---|---|---|---|---|---|---|
| Manufacturer’s product information (%) | Investigator‐initiated studies (%) | Manufacturer’s product information (%) | Investigator‐initiated studies (%) | |||||
| Binax Now Influenza A&B | Binax Inc., Portland, ME, USA | A and B | Nasal wash, nasal aspirate, nasopharyngeal swabs | 15 min | 100 | 59–80 [12, 22, 23] | 92–93 | 98–99 [12, 22] |
| Quick S‐Influ A/B ‘Seiken’ | Denka Seiken Co., Ltd, Tokyo, Japan | A and B | Nasal swab, nasal aspirate | 15 min | 90–93 | 81 [11] | 98–99 | 96 [11] |
| Influ‐A&B Respi‐Strip | Coris BioConcept, Gembloux, Belgium | A and B | Nasopharyngeal aspirates, washings or swabs | 15 min | 99 | ND | 88 | ND |
| Actim Influenza A&B | Medix Biochemica Ab, Kauniainen, Finland | A and B | Nasal swabs and nasopharyngeal aspirates | 10 min | 88–92 | ND | 99–100 | ND |
ND, not done—only samples positive for influenza A viruses were included in these investigations.